ARTICLE | Company News
BioVisioN, Novo Nordisk deal
November 1, 2004 8:00 AM UTC
BioVisioN received an undisclosed milestone payment from NVO under a 2002 deal for BioVisioN to use its Peptidomics technology to identify leads and targets for Type II diabetes (see BioCentury, May 1...